Meet our Research, Science, & Technology Leadership Team
Oxafence research and laboratory studies are led by Drs. Thomas Lendvay, James Chen, and Christopher Mores. Drs. Lendvay (lead author), Chen (theory originator), and Mores were also lead contributors in the 2020 WHO-led “Development of Methods for Mask and N95 Decontamination” (DeMaND) study. The DeMaND study demonstrated how Methylene Blue (MB), a protective dye, could inactivate SARS-CoV-2 on masks via Photodynamic Inactivation (PDI). Singletto, Inc. (the manufacturer of Oxafence technology) has continued to develop data supporting and expanding upon the DeMaND findings under Lendvay, Chen, and Mores’ leadership with the support of partners around the globe.
Dr Tom Lendvay
Chief Medical Officer
Thomas Lendvay, MD, is a Pediatric Urologist at Seattle Children’s Hospital and a professor in the Urology department at the University of Washington. He was honoured with the UW Medical School Inventor of the Year Award in 2018 for creating Crowd-Sourced Assessment of Technical Skills (CSATS) technology. He also currently serves as Chief Medical Officer for Tend-Health, Inc., a transformative microbiome restoration technology. His credentials include a Bachelor of Arts in Biology and German from Rice University and a Doctor of Medicine from Temple University.
Dr James Chen
Chief Scientific Officer
James Chen, MD, is a neurosurgeon who served for many years as the Chief Scientific Officer in a Photodynamic Therapy (PDT) oncology research company he co-founded. Dr Chen has 30 years of experience in PDT/PDI applications in many diverse areas, including oncology, ophthalmology, dermatology, obesity, and for inflammatory conditions. He is also the inventor of record on many PDT, Photodynamic Inactivation (PDI), and other patents. His credentials include a Bachelor of Arts from Evergreen State College, a Master of Science from the University of Washington, and a Doctor of Medicine from the University of Washington.
Dr Christopher Mores
Lab Director and Lead Researcher
Christopher Mores, ScD, is a virologist and epidemiologist whose research focuses on the role of viral characteristics in determining transmission potential. As director of a high-containment research laboratory at Milken Institute School of Public Health, he works closely with government and industry leaders on countermeasures to emerging disease threats. Dr Mores is also a professor at George Washington University, where the lab is located. His credentials include a Bachelor of Science in Biological Sciences from Rutgers University, a Master of Science in Tropical Public Health, and a Doctor of Science in Immunology and Infectious Diseases from Harvard University. Dr. Mores completed postdoctoral training in vector-borne and viral hemorrhagic fever viruses as a National Research Council Fellow at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID). He was the head of the Virology and Emerging Infections Department at the U.S. Naval Research Unit No. 6 in Peru, during which he investigated viral disease outbreaks, including the initial spread of Zika virus. Dr Mores has been engaged in ebola outbreak responses in West and Central Africa, where he continues to collaborate with the U.S. CDC and local partners to build more resilient health systems.
Singletto, Inc. is actively partnering with healthcare and consumer brands and manufacturers to provide Oxafence Active Protection solutions for existing and future products. Oxafence Active Protection technology can be formulated for pre-treatment or embedding into a variety of products and for specific use cases and/or multi-pathogen defence. Proprietary combinations of protective dyes (including Methylene Blue and Riboflavin/Vitamin B2) are utilized in the development of these products. Contact Info@OxafenceNZ.com for more information.